Study on basic and clinical application of Shufeng Jiedu Capsule in treating respiratory tract infection

Han, Yan; Xu, Jun; Zhu, Qiang; Yang, Li; Wang, Ying; Luo, Hua; Zhang, Tiejun

doi:10.1186/s13020-023-00749-1

Cited by 2 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In China, SFJD capsules are indicated for treating acute upper respiratory tract infections with symptoms such as fever, sore throat, headache, nasal congestion, runny nose, and cough ( Xia et al, 2018 ). In vitro and in vivo experiments have demonstrated that SFJD inhibits viral proliferation and attenuates inflammation associated with lung injury ( Han et al, 2023 ). Moreover, clinical trials have employed SFJD capsules for treating respiratory diseases characterized by symptoms such as fever or chills, sore throat, headache, nasal congestion, and cough ( Wang et al, 2020 ; Xia et al, 2020 ; Chen et al, 2021 ; Xia et al, 2021 ; Zhang et al, 2022a ).…”

Section: Introductionmentioning

confidence: 99%

Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial

Lu,

Yang,

Jin

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Background: The COVID-19 pandemic has had a profound global impact, although the majority of recently infected cases have presented with mild to moderate symptoms. Previous clinical studies have demonstrated that Shufeng Jiedu (SFJD) capsule, a Chinese herbal patent medicine, effectively alleviates symptoms associated with the common cold, H1N1 influenza, and COVID-19. This study aimed to assess the efficacy and safety of SFJD capsules in managing symptoms of mild to moderate COVID-19 infection.Methods: A randomized, double-blind, placebo-controlled trial was conducted from May to December 2022 at two hospitals in China. Mild and moderate COVID-19-infected patients presenting respiratory symptoms within 3 days from onset were randomly assigned to either the SFJD or placebo groups in a 1:1 ratio. Individuals received SFJD capsules or a placebo three times daily for five consecutive days. Participants were followed up for more than 14 days after their RT-PCR nucleoid acid test for SARS-CoV-2 turned negative. The primary outcome measure was time to alleviate COVID-19 symptoms from baseline until the end of follow-up.Results: A total of 478 participants were screened; ultimately, 407 completed the trial after randomization (SFJD, n = 203; placebo, n = 204). No statistically significant difference in baseline parameters was observed between the two groups. The median time to alleviate all symptoms was 7 days in the SFJD group compared to 8 days in the placebo group (p = 0.037). Notably, the SFJD group significantly attenuated fever/chills (p = 0.04) and headache (p = 0.016) compared to the placebo group. Furthermore, the median time taken to reach normal body temperature within 24 h was reduced by 7 hours in the SFJD group compared to the placebo group (p = 0.033). No deaths or instances of serious or critical conditions occurred during this trial period; moreover, no serious adverse events were reported.Conclusion: The trial was conducted in a unique controlled hospital setting, and the 5-day treatment with SFJD capsules resulted in a 1-day reduction in overall symptoms, particularly headache and fever/chills, among COVID-19-infected participants with mild or moderate symptoms. Compared to placebo, SFJD capsules were found to be safe with fewer side effects. SFJD capsules could potentially serve as an effective treatment for alleviating mild to moderate symptoms of COVID-19.Clinical Trial Registration: https://www.isrctn.com/, identifier ISRCTN14236594.

show abstract